161 related articles for article (PubMed ID: 27145327)
1. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Zhao C; Fan L; Qi F; Ou S; Yu L; Yi X; Ni B; Zheng Z; Lu J; Zhang C; Chen C; Lu X; Cheng L; Hu T; Ma Y
Anticancer Drugs; 2016 Aug; 27(7):689-94. PubMed ID: 27145327
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
[TBL] [Abstract][Full Text] [Related]
3. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus.
Zhu LZ; Xu S; Qian HL
World J Gastroenterol; 2018 Jun; 24(23):2501-2507. PubMed ID: 29930471
[TBL] [Abstract][Full Text] [Related]
4. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma.
Liu B; Zhu X; Gao S; Guo J; Wang X; Cao G; Zhu L; Liu P; Xu H; Chen H; Zhang X; Liu S; Kou F
J Interv Med; 2019 May; 2(2):91-96. PubMed ID: 34805879
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
9. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases.
Shao G; Liu R; Ding W; Lu L; Li W; Cao H; Liu R; Li C; Xiang H; Yang Z; Yang J; Song J; Wang J
Anticancer Drugs; 2018 Nov; 29(10):1021-1025. PubMed ID: 30134285
[TBL] [Abstract][Full Text] [Related]
11. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
12. A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment.
Qi C; Gao H; Li S; Zong H; Hao H; Zhang L
Genet Test Mol Biomarkers; 2020 Mar; 24(3):156-164. PubMed ID: 32101052
[No Abstract] [Full Text] [Related]
13. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.
Wu Y; Zheng S; Zhang Z; Chen G; Chen X; Zheng T; Guo X; Chen H; Wang M; Xie X; Zhang B
Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295504
[No Abstract] [Full Text] [Related]
14. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
15. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
[TBL] [Abstract][Full Text] [Related]
17. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
18. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
19. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin
Cui W; Fan W; Zhang Q; Wen J; Huang Y; Yang J; Li J; Wang Y
Oncotarget; 2017 Oct; 8(45):79165-79174. PubMed ID: 29108296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
